Skip to main content

AS/Spondyloarthritis

EULAR 2021 – Day 4 Report

Jun 17, 2021

It's been nearly two weeks since EULAR 21 ended. There were several presentations on the last day; notably, the late breaking abstracts and others. Here are a few of my favorites from Day 4, the final day of the meeting.

Read Article
Ten Things to Tell Patients About Diet and Rheumatic Disease: Dr. Eric Dein ( @ejdein1 ) https://t.co/q2Mc1gLZig https://t.co/iV5JO8m5Sv
Dr. John Cush @RheumNow( View Tweet )
Jun 16, 2021
Nr-axSpA vs axSpA — does it matter? Dr. Meral El Ramahi ( @MeralElRamahiMD ) reviews the panel from #EULAR2021. https://t.co/pfYvfsCbiA

Dr. John Cush @RheumNow( View Tweet )

Jun 16, 2021
During Day 2 there were great sessions devoted to RA, spondylarthritis, fatigue and more. We've compiled some of the highlights. https://t.co/NbBqPbbiUy https://t.co/FvsOhKtrHi
Dr. John Cush @RheumNow( View Tweet )
Jun 16, 2021
Why do female counterparts axSpA patients report worsening outcomes and worsening scores compared to their male counterparts? https://t.co/6hXp4Lemyk https://t.co/RTuhATrtG9
Dr. John Cush @RheumNow( View Tweet )
Jun 16, 2021

RheumNow Podcast - Best of EULAR 2021

Jun 11, 2021

Dr. Jack Cush reviews and highlights his favorite abstracts and presentations from last week's virtual EULAR 2021 meeting.

Read Article
Video: The PsA SpA Paradox of Choice Dr. Rachel Tate ( @uptoTate) reviews Dr. Laura Coates' presentation Personalized Treatment Strategies in Psoriatic Arthritis, given at the virtual #EULAR2021 meeting. https://t.co/Yg12SHR1MF https://t.co/UiCYDU5XGc
Dr. John Cush @RheumNow( View Tweet )
Jun 08, 2021
Video: Nr-axSpA vs axSpA — does it matter? Dr. Meral El Ramahi (@MeralElRamahiMD ) #EULAR2021 https://t.co/ocyR4ka8zO https://t.co/DxHjM0stKo
Dr. John Cush @RheumNow( View Tweet )
Jun 08, 2021
#EULAR2021 - Day 3 Report https://t.co/X7zxsKW8eL https://t.co/OKu5Mgodlo
Dr. John Cush @RheumNow( View Tweet )
Jun 08, 2021

EULAR 2021 - Day 3 Report

Jun 07, 2021

Here are a few notable presentations from this past Friday, Day 3 of the EULAR 2021 virtual meeting.

Read Article

Israel provides COVID vaccine answers for rheumatic disease patients

Jun 07, 2021

The question as to how autoimmune rheumatic disease patients fare with the COVID vaccine is one being asked in rheumatologists’ offices everywhere this year, and at the EULAR 2021 Virtual Congress, data presented from Israel, one of the first countries to vaccinate on a broad scale, has

Read Article
Find all your AS/Spondyloarthritis coverage from #EULAR2021 in one spot. https://t.co/owm8LQzHXr https://t.co/5YmDFOvolF
Dr. John Cush @RheumNow( View Tweet )
Jun 07, 2021
OP0140 at #EULAR2021: ➡️Obs, prospect Nordic study characterized axSpA pts w/ high BASDAI + ASDAS & multiple bDMARD use (indicating difficult to tx dz) ➡️1 in 10 received at least 3 bDMARDs *⃣Multiple switchers were more often F, had higher b/l dz activity, & psoriasis @Rheumnow https://t.co/syq0szVWKe
Meral K. El Ramahi, MD @MeralElRamahiMD( View Tweet )
Jun 06, 2021
⭐️TORTUGA = PII trial that showed filgotinib (Jak1-i) signif improv SPARCC MRI scores (BM edema) in the spine + SIJ vs PBO in pts w/ active AS ⭐️OP0141 = post-hoc analysis that showed stat signif ⬇️ of CANDEN MRI scores (new bone format) w/ filgot at wk12 #EULAR2021 @Rheumnow https://t.co/RIpYIMcx1Q
Meral K. El Ramahi, MD @MeralElRamahiMD( View Tweet )
Jun 06, 2021
➡️Netakimab = IL17Ai approved for AS, PsA, & Pso in Russia & Belarus

Meral K. El Ramahi, MD @MeralElRamahiMD( View Tweet )

Jun 06, 2021
#EULAR2021 POS0236 Comparison of work productivity b/w CBP w & w/o AxSpA - 2 years from SPACE cohort ⭐️AxSpA showed significant ⬇️ in work productivity loss (WPL) compared to CBP wo AxSpA Can use to counsel AxSpA patients that we have effective Rx for return to work @RheumNow

Eric Dein @ejdein1( View Tweet )

Jun 06, 2021
#EULAR2021 POS0237: Gut dysbiosis linked to worse disease status in axSpA. ⭐️Dysbiosis in 33% of AxSpA vs 17% of controls wo rheumatic disease ⭐️Gut dysbiosis associated with worsening disease activity @RheumNow https://t.co/rRl4Zbs7xc
Eric Dein @ejdein1( View Tweet )
Jun 06, 2021
6. Rheum disease activity was stable with COVID vaccination. (RA, PsA, axSpA, SLE - total n = 597) 7/ LB0003 #EULAR2021 @RheumNow https://t.co/xxkrunjPa0
David Liew @drdavidliew( View Tweet )
Jun 06, 2021

RheumNow’s expanded coverage of the #EULAR2021 Annual meeting is sponsored in part by Novartis, Bristol Myers Squibb, and Janssen. All content chosen by RheumNow & its faculty.

Dr. John Cush @RheumNow( View Tweet )

Jun 06, 2021
Attention bosses! AxSpA patients who were older and worse disease activity associated with more sick leave ⭐️male gender and higher education associated with less sick leave Abs#POS0238 #EULAR2021 @RheumNow https://t.co/aSs0BCHjau
Robert B Chao, MD @doctorRBC( View Tweet )
Jun 05, 2021
EULAR 2021 - Day 2 Podcasts Check out this compilation of our EULAR 2021 Day 2 broadcasts below. You can also follow the EULAR 2021 RheumNow podcasts on iTunes and Soundcloud. https://t.co/GskToSkfLk https://t.co/nF2FkHgBtu
Dr. John Cush @RheumNow( View Tweet )
Jun 05, 2021
Gut dysbiosis linked to worse disease status in AxSpA ⭐️higher dysbiosis associated w/ worse EvalGlobal, ASDAS-CRP, BASDAI, BASFI, VAS pain ⭐️comparing dysbiosis vs. non-dysbiosis group - significant difference in BASDAI, BASFI, EvalGlobal Abs#POS0237 #EULAR2021 @RheumNow

Robert B Chao, MD @doctorRBC( View Tweet )

Jun 05, 2021
#EULAR2021 POS0227 recs all patients try subQ MTX before bDMARD. Mirza et al: ⬆️ efficacy & ⬇️side effects with subQ. May not be for all pts, but subQ ⬆️ efficacy than high-dose PO MTX. ⬇️ GI side effects, but ⬆️ ulcers/hair loss (use folate/leucovorin for this) @RheumNow

Eric Dein @ejdein1( View Tweet )

Jun 05, 2021
Yesterday at #EULAR2021: Spacing trial: success in taper anti-TNF for stable SpA. POS0229 C-OPTIMSE study: Certolizumab w/d for SpA remission (continue full dose vs. 1/2 dose vs. placebo). Placebo group had ⬆️ activity scores, 77% flared. Ok to taper, but won't stop Rx @Rheumnow

Eric Dein @ejdein1( View Tweet )

Jun 05, 2021
RheumNow’s expanded coverage of the #EULAR2021 Annual meeting is sponsored in part by Novartis, Bristol Myers Squibb, and Janssen. All content chosen by RheumNow & its Faculty.

Dr. John Cush @RheumNow( View Tweet )

Jun 05, 2021
×